The long-acting anti-C5 ravulizumab results in C3 binding to PNH red cells similar to its parental molecule eculizumab.

[1]  J. Lee,et al.  Long‐term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2‐year results from two pivotal phase 3 studies , 2022, European journal of haematology.

[2]  P. Scheinberg,et al.  Categorizing hematological response to eculizumab in paroxysmal nocturnal hemoglobinuria: a multicenter real-life study , 2021, Bone Marrow Transplantation.

[3]  R. Wells,et al.  Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies , 2020, British journal of haematology.

[4]  J. Maciejewski,et al.  Characterization of breakthrough hemolysis events observed in the phase III randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria , 2020, Haematologica.

[5]  P. Scheinberg,et al.  Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT , 2019, Front. Immunol..

[6]  Zhao-Xue Yu,et al.  Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action , 2018, PloS one.

[7]  A. Risitano,et al.  Eculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytes , 2017, Journal of Hematology & Oncology.

[8]  D. Ricklin,et al.  Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation. , 2017, Blood.

[9]  Patrizia Ricci,et al.  Complement C3dg-mediated erythrophagocytosis: implications for paroxysmal nocturnal hemoglobinuria. , 2015, Blood.

[10]  J. Maciejewski,et al.  Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria , 2013, British journal of haematology.

[11]  L. Luzzatto,et al.  The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment. , 2012, Blood.

[12]  T. Kinoshita,et al.  Persistently high quality of life conferred by coexisting congenital deficiency of terminal complement C9 in a paroxysmal nocturnal hemoglobinuria patient. , 2012, Blood.

[13]  L. Luzzatto,et al.  correspondence: Pregnancy in PNH: another eculizumab baby , 2010, British journal of haematology.

[14]  S. Richards,et al.  Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization , 2010, Haematologica.

[15]  A. Zanella,et al.  Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. , 2009, Blood.